Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gefitinib”

348 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 348 results

Large-scale testing (Phase 3)UnknownNCT03203590
What this trial is testing

Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients

Who this might be right for
2-year Disease-Free Survival
Sun Yat-sen University 590
Testing effectiveness (Phase 2)UnknownNCT01965275
What this trial is testing

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Who this might be right for
Self EfficacyDrug Toxicity
Anhui Medical University 20
Testing effectiveness (Phase 2)UnknownNCT02951637
What this trial is testing

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Who this might be right for
Lung Adenocarcinoma
Shanghai Chest Hospital 300
Not applicableEnded earlyNCT02932345
What this trial is testing

Gefitinib Long-term Survivor Study

Who this might be right for
EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
AstraZeneca 59
Testing effectiveness (Phase 2)Study completedNCT00177242
What this trial is testing

Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma

Who this might be right for
Cancer
University of Pittsburgh 45
Large-scale testing (Phase 3)Study completedNCT00455936
What this trial is testing

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

Who this might be right for
Lung Cancer
National Cancer Center, Korea 315
Early research (Phase 1)Study completedNCT00993499
What this trial is testing

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 44
Large-scale testing (Phase 3)UnknownNCT01158170
What this trial is testing

Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)

Who this might be right for
Non-small Cell Lung Cancer
Zhejiang Cancer Hospital 200
Large-scale testing (Phase 3)Active Not RecruitingNCT03787992
What this trial is testing

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 358
Testing effectiveness (Phase 2)Active Not RecruitingNCT03122717
What this trial is testing

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Dana-Farber Cancer Institute 48
Testing effectiveness (Phase 2)Study completedNCT00242918
What this trial is testing

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

Who this might be right for
Prostate Cancer
Benaroya Research Institute 29
Testing effectiveness (Phase 2)Study completedNCT00103051
What this trial is testing

Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Not applicableUnknownNCT02804100
What this trial is testing

Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients

Who this might be right for
Carcinoma, Non-Small-Cell LungBronchial NeoplasmsCarcinoma, Bronchogenic+2 more
Wenzhou Medical University 200
Early research (Phase 1)Study completedNCT00083057
What this trial is testing

Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Head and Neck Cancer
National Institutes of Health Clinical Center (CC) 30
Testing effectiveness (Phase 2)WithdrawnNCT01928160
What this trial is testing

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Who this might be right for
Recurrent Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00049062
What this trial is testing

Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
The University of Texas Health Science Center at San Antonio
Testing effectiveness (Phase 2)Study completedNCT00027690
What this trial is testing

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Who this might be right for
Recurrent Uterine Corpus Carcinoma
National Cancer Institute (NCI) 56
Post-approval studies (Phase 4)Study completedNCT00770588
What this trial is testing

Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
AstraZeneca 296
Early research (Phase 1)Study completedNCT00162318
What this trial is testing

A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Carcinoma
Eli Lilly and Company 30
Testing effectiveness (Phase 2)UnknownNCT01755923
What this trial is testing

Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Peking Union Medical College Hospital 60
Load More Results